MYC and neoplasm: Albeit conclusive clinical evidence linking MYC activity to immunotherapy response is still lacking, a strong body of preclinical studies unraveled a prominent role of oncogenic MYC in evading immune surveillance, in particular by promoting the expression of surface receptors and cytokines (e.g., PD‐L1 and CCL9, respectively) that establish immune tolerance in the tumor microenvironment [16].